Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:250606.
doi: 10.1155/2010/250606. Epub 2010 Dec 28.

Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma

Bassel Tarakji  1 , Omar Kujan, Mohammad Z Nassani
Affiliations

Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma

Bassel Tarakji et al. J Cancer Epidemiol. 2010.

Abstract

Context. Immunohistochemical stains for p53 are used as a diagnostic marker associated with malignancy in several histologic types of salivary gland tumors. This marker may be useful in differentiating pleomorphic adenoma (PA) from carcinoma ex pleomorphic adenoma (CPA), as these tumors are often difficult to distinguish on the basis of morphology alone. Objective. to evaluate whatever inactivation of tumor suppressor gene (p53) increases with the tumor progression from normal salivary tissue to PA and eventually CPA. Design. Paraffin blocks of 29 cases of PA, which were surrounded by normal parotid gland, and 27 cases of carcinoma ex pleomorphic adenoma were retrieved and validated. In all cases of carcinoma ex pleomorphic adenoma, a PA "ghost" was identified, and the malignant element was either undifferentiated carcinoma or adenocarcinoma. Results. The results showed negative nuclear expression of P53 in normal parotid gland. Nuclear P53 was expressed strongly in 6/29 (20.7%) pleomorphic salivary adenoma and 10/27 (37%) carcinoma ex pleomorphic adenoma. Conclusion. Our data suggest that inactivation of p53 may play an important role in the evolution of pleomorphic salivary adenoma and carcinoma ex pleomorphic adenoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Showing negative nuclear staining of p53 in normal salivary tissue. Original magnification x40.
Figure 2
Figure 2
Showing strong p53 staining in pleomorphic salivary adenoma. Original magnification x40.
Figure 3
Figure 3
Showing moderate p53 staining in pleomorphic salivary adenoma. Original magnification x40.
Figure 4
Figure 4
Showing low nuclear staining of p53 in pleomorphic salivary adenoma. Original magnification x40.
Figure 5
Figure 5
Showing strong p53 staining of nuclei in CPA. Original magnification x40.
Figure 6
Figure 6
Showing moderate p53 nuclear staining in CPA. Original magnification x40.
Figure 7
Figure 7
Showing low nuclear staining of p53 in CPA. Original magnification x40.
Figure 8
Figure 8
Showing p53 negative control for CPA. Original magnification x40.
See this image and copyright information in PMC

References

    1. Ungari C, Paparo F, Colangeli W, Iannetti G. Parotid glands tumours: overview of a 10-years experience with 282 patients, focusing on 231 benign epithelial neoplasms. European Review for Medical and Pharmacological Sciences. 2008;12(5):321–325. - PubMed
    1. Demasi APD, Furuse C, Soares AB, Altemani A, Araújo VC. Peroxiredoxin I, platelet-derived growth factor A, and platelet-derived growth factor receptor α are overexpressed in carcinoma ex pleomorphic adenoma: association with malignant transformation. Human Pathology. 2009;40(3):390–397. - PubMed
    1. Suzuki H, Fujioka Y. Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland. Diagnostic Molecular Pathology. 1998;7(4):224–231. - PubMed
    1. Numata T, Hiruma K, Tsukuda T, Asano T. Malignant mixed tumor. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 2004;31(3):314–317. - PubMed
    1. Yamamoto Y, Kishimoto Y, Wistuba II, et al. DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining. Pathology International. 1998;48(4):265–272. - PubMed